NASDAQ:KLDO

Kaleido Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy KLDO

*Your capital is at risk

$0.0001

+0 (+0%)

At Close: Jun 03, 2026

Kaleido Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 7.33M and sold 8.27K KLDO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	7.33M shares
● Sell	8.27K shares
96% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 30, 2021 Buy	Stock Option (Right to Buy) A-Award	Quinn Anthony G. Director	Director	15 000 Value: $111.6K
Jun 30, 2021 Buy	Stock Option (Right to Buy) A-Award	Von Maltzahn Geoffrey Director	Director	15 000 Value: $111.6K
May 05, 2021 Buy	Restricted Stock Units	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	6 707 Value: $0
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	40 000 Value: $392.4K
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	40 000 Value: $347.6K
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	40 000 Value: $240.0K
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	55 000 Value: $360.8K
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	125 000 Value: $958.8K
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	125 000 Value: $958.8K
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	55 000 Value: $360.8K
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	40 000 Value: $240.0K
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	40 000 Value: $347.6K
May 05, 2021 Buy	Stock Option (Right to Buy)	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	40 000 Value: $392.4K
May 05, 2021 Buy	Restricted Stock Units	Van Hylckama Vlieg Johan Chief Scientific Officer	Officer	6 707 Value: $0
Mar 01, 2021 Buy	Stock Option (Right to Buy) A-Award	Menichella Daniel L Chief Executive Officer	CEO / President	90 000 Value: $882.9K
Mar 01, 2021 Buy	Stock Option (Right to Buy) A-Award	Korn Jerald General Counsel	Officer	60 000 Value: $588.6K
Mar 01, 2021 Buy	Stock Option (Right to Buy) A-Award	Duke William E. Chief Financial Officer	C-Suite Officer	60 000 Value: $588.6K
Mar 01, 2021 Buy	Stock Option (Right to Buy) A-Award	Duke William E. Chief Financial Officer	C-Suite Officer	60 000 Value: $588.6K
Mar 01, 2021 Buy	Stock Option (Right to Buy) A-Award	Korn Jerald General Counsel	Officer	60 000 Value: $588.6K
Mar 01, 2021 Buy	Stock Option (Right to Buy) A-Award	Menichella Daniel L Chief Executive Officer	CEO / President	90 000 Value: $882.9K
Feb 08, 2021 Buy	Common Stock P-Purchase	Menichella Daniel L Chief Executive Officer	CEO / President	20 000 Value: $230.0K
Feb 08, 2021 Buy	Common Stock P-Purchase	Menichella Daniel L Chief Executive Officer	CEO / President	20 000 Value: $230.0K
Feb 08, 2021 Buy	Common Stock P-Purchase	Flagship Ventures Fund Iv General Partner Llc 10 Percent Owner	10% Owner	71 667 Value: $824.2K
Feb 08, 2021 Buy	Common Stock P-Purchase	Flagship Ventures Fund Iv General Partner Llc 10 Percent Owner	10% Owner	71 666 Value: $824.2K
Feb 08, 2021 Buy	Common Stock P-Purchase	Flagship Ventures Fund Iv General Partner Llc 10 Percent Owner	10% Owner	71 667 Value: $824.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KALEIDO BIOSCIENCES INC.

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disea...

Read Full Profile Here